This study investigates the potential of seminal fluid as a non-invasive liquid biopsy for detecting clinically significant prostate cancer. Seminal fluid samples were collected at home from 279 men scheduled for prostate biopsy, and their cell-free DNA (cfDNA) underwent methylation analysis. Researchers characterized seminal cfDNA, identifying granulocytes and sperm as primary contributors, but confirming the detectable presence of prostate-derived cfDNA. Fragment-level methylation features were analyzed to identify signals associated with clinically significant prostate cancer, highlighting the promise of this approach for diagnosis and monitoring.
Pirmoradi S, Vaghefi Moghaddam S, Ardalan M, et al.
PloS one ·
This study introduces an artificial intelligence framework utilizing graph neural networks (GNNs) for prostate cancer risk stratification, integrating mRNA expression profiles with functional interaction networks. The aim is to classify patients into low-, medium-, and high-risk groups, defined by Gleason scores, to guide treatment decisions and prevent overtreatment. Developed using TCGA data, the model achieved an overall accuracy of 80% and high AUCs on an independent test set. Differentially expressed genes were identified for each risk group, highlighting the molecular heterogeneity of disease progression.
This prospective observational study investigated the prognostic value of circulating tumor DNA (ctDNA)-derived tumor fraction (TFx) and copy-number alterations (CNAs) in 78 patients with metastatic castration-resistant prostate cancer (mCRPC) receiving tandem [225Ac]Ac-/[177Lu]Lu-PSMA-617 radioligand therapy. Findings revealed that ctDNA-derived TFx serves as a dynamic biomarker for treatment response and progression risk, with a significantly increased risk of progression (HR 4.9) when modeled as a time-dependent variable. Furthermore, a high CNA burden was associated with shorter median overall survival (8.3 vs 13.8 months). The study identified recurrent CNAs affecting key tumor suppressor genes and highlighted the potential of these ctDNA-based biomarkers for clinical stratification and real-time monitoring.
This study characterized the prevalence of KRAS G12C mutations in genitourinary malignancies, an area with limited data despite the approval of targeted therapies. Comprehensive genomic profiling was performed on over 13,000 samples of renal clear cell carcinomas, urothelial bladder carcinomas, and prostate acinar adenocarcinomas. Results indicated that KRAS G12C mutations are infrequent in these tumors, with an incidence of 0% in renal carcinomas, 0.6% in urothelial bladder carcinomas, and less than 0.01% in prostate adenocarcinomas. Despite their low frequency, these mutations represent an emerging therapeutic target, warranting further investigation, particularly in basket trials for patients harboring this actionable alteration.
A new study developed and validated a non-invasive urine DNA methylation assay for prostate cancer detection, aiming to improve the specificity of PSA screening. This test, based on the methylation of two genes (ADD3 and GSX2), was developed retrospectively in 348 participants and prospectively validated in 200 participants in a multicenter study. It demonstrated robust diagnostic performance with AUCs of 0.86 and 0.91, and specificity above 90%. Integrating this tool could potentially avert approximately 55% of unnecessary biopsies without compromising cancer detection.
This study investigates how altered enhancers in prostate cancer cooperate within the 3D chromatin architecture to drive oncogenic programs. Researchers identified prostate cancer-specific enhancers that form highly nested interactions with promoters, coalescing into multi-connected hubs. CRISPR/Cas9 perturbations distinguished distinct enhancer classes: central enhancers, whose deletion collapses hub-wide activity and impairs cell proliferation, and redundant enhancers, whose deletion has minimal impact due to compensatory architectural rewiring. The transcription factor FOXA1 was found to directly bind and regulate these distinct enhancer classes. These findings suggest that enhancers function in a coordinated manner and open new avenues for precision therapies.